AMBQ Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $17.9 million, up from $15.7 million in Q1 2025 but down from $20.3 million in Q2 2024.
Gross Profit: Non-GAAP gross profit was $7.6 million (42.7% of revenue), compared to $7.4 million (47.1%) in Q1 2025 and $6.7 million (32.9%) in Q2 2024.
Operating Expenses: Non-GAAP operating expenses were $13.8 million, slightly up from $13.1 million in Q1 2025 but down from $14.4 million in Q2 2024.
Net Loss: $8.5 million or $18.90 per share, compared to a loss of $8.3 million in Q1 2025 and $10.6 million in Q2 2024. Non-GAAP net loss was $5.9 million.
Cash Position: Cash and cash equivalents were $47.5 million at the end of Q2 2025, bolstered by a successful IPO that raised $97.2 million.

2. Strategic Updates and Business Highlights

Ambiq is focusing on expanding its market presence beyond China, which saw a significant drop in sales contribution from 42% in Q2 2024 to 11.5% in Q2 2025.
The company is investing in R&D to enhance its Apollo product line and develop the new Atomic product line, targeting applications in wearables, medical devices, and edge AI.
A notable partnership with Whoop was highlighted, where Ambiq's technology is integrated into their new fitness tracker, enhancing battery efficiency and AI capabilities.

3. Forward Guidance and Outlook

For Q3 2025, Ambiq expects revenue between $17.5 million and $18 million, with non-GAAP loss per share projected between $0.35 and $0.28.
The company remains cautiously optimistic about the second half of the year, anticipating improved performance despite previous uncertainties regarding tariffs.

4. Bad News, Challenges, or Points of Concern

Year-over-year revenue decline indicates challenges in maintaining sales levels, particularly with the strategic shift away from China.
The company acknowledged potential impacts from tariffs, which had caused some demand pull-ins in Q2.
Non-GAAP operating expenses are rising, which could pressure profitability if revenue growth does not accelerate.

5. Notable Q&A Insights

Ambiq defines edge AI broadly, with over half of its business reportedly involving intelligent devices.
The company is exploring IP licensing for its SPOT technology, targeting sectors like data centers and automotive, but acknowledges that development may take several years.
There is a positive outlook on order trends, with a typical lead time of 16 weeks for customer orders, suggesting a healthy second half.
Ambiq is actively working on non-wearable applications, with 17% of its funnel directed towards medical and industrial sectors, indicating diversification efforts.

Overall, while Ambiq has made strides in revenue growth and strategic partnerships, it faces challenges in maintaining sales levels and navigating market uncertainties. The company's focus on expanding its product offerings and geographic reach will be critical in the coming quarters.

AMBQ — Ambiq Micro, Inc.